- Vardenafil
-
-
2026-08-27
- CAS:224789-15-5
- Min. Order: 1KG
- Purity: 98
- Supply Ability: 1000 KG
|
| | Vardenafil dihydrochloride Basic information |
| Product Name: | Vardenafil dihydrochloride | | Synonyms: | VARDENAFIL CITRATE;VARDENAFILDIHYDROCHLORIDE(SUBJECTTOPATENTFREE);1-[[3-(1,4-Dihydro-5-methyl-4-oxo-7-propylimidazo[5,1-f][1,2,4]triazin-2-yl)-4-ethoxyphenyl]sulfonyl]-4-ethyl-piperazine dihydrochloride;Vardenafil dihydrochloride;2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonyl-phenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one dihydrochloride;2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one dihydrochloride;2-[2-ethoxy-5-[(4-ethyl-1-piperazinyl)sulfonyl]phenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one;Vardenafil dihydrochloride solution | | CAS: | 224789-15-5 | | MF: | C23H33ClN6O4S | | MW: | 525.07 | | EINECS: | 200-659-6 | | Product Categories: | 11;Active Pharmaceutical Ingredients;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds;LEVITRA;224789-15-5 | | Mol File: | 224789-15-5.mol |  |
| | Vardenafil dihydrochloride Chemical Properties |
| Melting point | 214-216°C | | storage temp. | Refrigerator | | solubility | DMSO (Slightly, Heated), Methanol (Slightly) | | form | Solid | | color | White to Off-White | | InChIKey | NOIHTGOGFDFCBN-UHFFFAOYSA-N | | SMILES | C1N(S(=O)(=O)C2C=C(C3NC(=O)C4=C(C)N=C(CCC)N4N=3)C(OCC)=CC=2)CCN(CC)C1.Cl.Cl | | CAS DataBase Reference | 224789-15-5(CAS DataBase Reference) |
| | Vardenafil dihydrochloride Usage And Synthesis |
| Chemical Properties | White to Off-White Cyrstalline Solid | | Uses | erectile dysfunction, PD5 inhibitor | | Uses | Vardenafil Dihydrochloride Salt is a selective phosphodiesterase type 5 (PDE5) inhibitor. | | Uses | A selective phsphodiesterase type 5 (PDE5) inhibitor. | | in vivo | Vardenafil dihydrochloride (0.03 mg/kg; i.v.) exhibits facilitator effects in rats with cavernous nerve injury[4].
Vardenafil dihydrochloride (0.17 mg/kg; i.v.; once daily; 7 d) protects liver against Con A–induced hepatitis, and decreases the expression of NF-B and iNOS in hepatic tissue[5].
Vardenafil dihydrochloride (10 mg/kg; p.o.; once daily; 25 weeks) prevents the reduction of tissue cGMP levels and the increase in 3-NT generation in ZDF hearts[6].
| Animal Model: | Male rat (9-week-old) underwent surgery for laparotomy or bilateral cavernous nerve (CN) crush injury[4] | | Dosage: | 0.03 mg/kg | | Administration: | Intravenous injection | | Result: | Restored normal erectile responses with a combind administration of BAY 60-4552 (0.03, 0.3 mg/kg). |
| Animal Model: | Liver injury induced by Con A in male Swiss albino mice (20 ± 2 g)[5] | | Dosage: | 0.17 mg/kg | | Administration: | Intravenous injection; once daily, for 7 days; as a pretreatment | | Result: | Reduced the levels of serum transaminases and alleviated Con A-induced hepatitis. |
| Animal Model: | Male 7-week-old Zucker diabetic fatty (ZDF) rats (preserved ejection fraction, HFpEF)[6] | | Dosage: | 10 mg/kg | | Administration: | Oral gavage; once daily, for 25 weeks | | Result: | Improved myofilament function in diabetic rat hearts. |
| | IC 50 | PDE5: 0.7 nM (IC50); PDE1: 180 nM (IC50); PDE6: 11 nM (IC50) |
| | Vardenafil dihydrochloride Preparation Products And Raw materials |
|